Picoplatin Phase 2 Small Cell Lung Cancer Trial Promising
Poniard Pharmaceuticals will present updated results from its Phase 2 trial of picoplatin for lung cancer treatment, including one-year survival data, during a poster discussion session at the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer in Seoul, Korea.
A phase 2 study of picoplatin monotherapy for patients with small cell lung cancer (SCLC) who have resistant or refractory disease or have relapsed within 180 days of completing first-line, platinum-containing chemotherapy.
Picoplatin, the Company's lead product candidate, is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2005 for picoplatin for the treatment of SCLC.
Poniard is currently evaluating intravenous picoplatin in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.